A study of the Oxidative stress and Antioxidant status in diabetic subjects who are on treatment with Metformin

Background: Oxidative stress plays an important role in the pathogenesis of DM and its complications. However, antioxidant status and its contribution to type 2 DM are less explored in South Indian population. Metformin, is a biguanide anti hyperglycemic agent used for the management of type 2 diabetes. Aim:  To study the alteration in oxidant and antioxidant status in type 2 diabetic subjects on treatment with Metformin and to evaluate the effect of metformin in improving the total antioxidant status. Methodology: In this cross sectional study, all subjects were T2DM patients, on metformin monotherapy (500 mg, bd) and were grouped into two - Group 1 and Group 2 for the study purpose, based on their HbA1c values. Baseline parameters (B.P, Waist Hip ratio, BMI, family history), glycemic status, lipid profile, FRAP, TBARS and serum Metformin levels were assayed. Fasting and postprandial blood specimens were collected and plasma glucose concentrations were measured by standard methods. Fasting plasma total antioxidant capacity (TAC) was measured by ferric reducing ability of plasma (FRAP) assay. Oxidative stress was evaluated and measured as TBARS and the values were compared among the two groups. Results: TBARS levels were higher and FRAP levels were significantly lower in Group I subjects compared to Group II subjects and can be explained due to increased superoxide ions and reduced activity of S. O. D. Conclusion: It may be concluded that total antioxidant status is lower in type 2 diabetic subjects of Group 1 category compared to diabetic subjects in the Group 2 and it may be related to the beneficial effects of the biguanide, Metformin

A study of the Oxidative stress and Antioxidant status in diabetic subjects who are on treatment with Metformin

Background: Oxidative stress plays an important role in the pathogenesis of DM and its complications. However, antioxidant status and its contribution to type 2 DM are less explored in South Indian population. Metformin, is a biguanide anti hyperglycemic agent used for the management of type 2 diabetes. Aim:  To study the alteration in oxidant and antioxidant status in type 2 diabetic subjects on treatment with Metformin and to evaluate the effect of metformin in improving the total antioxidant status. Methodology: In this cross sectional study, all subjects were T2DM patients, on metformin monotherapy (500 mg, bd) and were grouped into two - Group 1 and Group 2 for the study purpose, based on their HbA1c values. Baseline parameters (B.P, Waist Hip ratio, BMI, family history), glycemic status, lipid profile, FRAP, TBARS and serum Metformin levels were assayed. Fasting and postprandial blood specimens were collected and plasma glucose concentrations were measured by standard methods. Fasting plasma total antioxidant capacity (TAC) was measured by ferric reducing ability of plasma (FRAP) assay. Oxidative stress was evaluated and measured as TBARS and the values were compared among the two groups. Results: TBARS levels were higher and FRAP levels were significantly lower in Group I subjects compared to Group II subjects and can be explained due to increased superoxide ions and reduced activity of S. O. D. Conclusion: It may be concluded that total antioxidant status is lower in type 2 diabetic subjects of Group 1 category compared to diabetic subjects in the Group 2 and it may be related to the beneficial effects of the biguanide, Metformin

Giant Intraosseous Schwannoma of the Ileopubic Ramus

Schwannomas are the most common tumors of the peripheral nerves. Intraosseous schwannoma is a rare entity; approximately 200 cases are described in the world literature, with only 1 involving the ileopubic ramus. To the authors' knowledge, this article is the first to describe a giant intraosseous schwannoma of the ileopubic ramus, its clinical presentation and radiographic aspect, its histological findings, its biological behavior, and the differential diagnosis. It is also the first to describe surgical treatment of this entity. A 63-year-old woman presented with paroxysmal pain at the right groin. Radiographs showed a multilocular lytic lesion of the right ileopubic ramus, extending from the acetabulum to the pubic symphysis. Magnetic resonance imaging revealed extraosseous extension in the pelvis and in the anteromedial region of the right thigh. An incisional biopsy revealed fibroconnective tissue with sparse spindle cells in a myxoid stroma; diffuse expression of S100 protein was observed by immunohistochemistry. Intraosseous neurofibroma was the first histopathologic diagnosis. The 123834-cm lesion was entirely removed via a Letournel ileoinguinal approach. Reconstruction of the ileopubic ramus was performed with an autologous bone graft taken from the omolateral iliac crest and fixed by a pelvic reconstruction plate. Histopathological examination revealed Antoni A and B patterns with Verocay bodies, no mitosis or cellular atypia, and diffuse expression of S100 protein by immunohistochemistry, all features indicative of a benign schwannoma. The patient returned to activities of daily living with no limitations. No recurrence had occurred 24 months postoperatively

Intraosseous schwannoma of the glenoid: case report and literature review

Intraosseous schwannomas represent an extremely rare subgroup of schwannomas, accounting for <1% of all primary bone tumors. They mostly occur in the mandible, the maxilla, the sacrum, and they are also seen in long bones. We herein report a rare presentation of an intraosseous schwannoma in the glenoid of a 49-year-old patient. She complained of shoulder pain and was referred to the orthopaedic oncologist after detection of a suspicious lesion on imaging. Biopsy revealed benign spindle cells and immunohistochemistry was positive for S100. Because of the rarity of these intraosseous schwannomas it is important to recognize their radiological and histological features and make a differential diagnosis with other lytic tumors. Only if these characteristics are recognized, correct treatment can be given with definite curettage and bone grafting and correct follow-up with avoidance of unnecessary adjuvant therapy